| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
994 |
964 |
$26K |
| 99214 |
|
1,947 |
1,762 |
$25K |
| 80307 |
|
1,438 |
1,378 |
$9K |
| G0396 |
Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes |
1,599 |
1,508 |
$3K |
| 99213 |
|
180 |
173 |
$1K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
143 |
136 |
$480.60 |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
109 |
108 |
$263.08 |
| G8950 |
Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented |
802 |
727 |
$0.00 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
822 |
731 |
$0.00 |
| G9906 |
Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) |
610 |
557 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
131 |
125 |
$0.00 |
| 1036F |
|
923 |
822 |
$0.00 |
| G9902 |
Patient screened for tobacco use and identified as a tobacco user |
604 |
558 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
305 |
286 |
$0.00 |
| G9583 |
Patients prescribed opiates for longer than six weeks |
566 |
517 |
$0.00 |
| G2197 |
Patient screened for unhealthy alcohol use using a systematic screening method and not identified as an unhealthy alcohol user |
21 |
20 |
$0.00 |
| G8418 |
Bmi is documented below normal parameters and a follow-up plan is documented |
12 |
12 |
$0.00 |
| 1123F |
|
32 |
28 |
$0.00 |
| 4004F |
|
553 |
505 |
$0.00 |
| 1124F |
|
985 |
799 |
$0.00 |
| G9578 |
Documentation of signed opioid treatment agreement at least once during opioid therapy |
821 |
743 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
1,045 |
931 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
1,997 |
1,800 |
$0.00 |
| G8783 |
Normal blood pressure reading documented, follow-up not required |
165 |
150 |
$0.00 |
| G9622 |
Patient not identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method |
880 |
798 |
$0.00 |
| G9577 |
Patients prescribed opiates for longer than six weeks |
795 |
724 |
$0.00 |
| G0444 |
Annual depression screening, 5 to 15 minutes |
119 |
118 |
$0.00 |
| G8730 |
Pain assessment documented as positive using a standardized tool and a follow-up plan is documented |
597 |
555 |
$0.00 |
| G9584 |
Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy |
313 |
285 |
$0.00 |
| G0030 |
Patient screened for tobacco use and received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling, pharmacotherapy, or both), if identified as a tobacco user |
12 |
12 |
$0.00 |
| 99212 |
|
18 |
17 |
$0.00 |